Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
| ▸ | OGA | O60502 | 8/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415985 | 0.86 | MET (0.59) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL3415847 | 0.80 | MET (0.39) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL3412281 | 0.77 | DYRK1A (0.43) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL4513787 | 0.77 | FYN (0.53) | METDYRK1ADYRK1BOGA | |
| SCHEMBL3411255 | 0.77 | DYRK1A (0.40) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL3411454 | 0.75 | MET (0.49) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL1163354 | 0.75 | MET (0.49) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL3416395 | 0.75 | MET (0.36) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL3411404 | 0.75 | DYRK1A (0.43) | METDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL13692807 | 0.74 | MET (0.39) | METOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | MET 1/4885DYRK1A 560/4885DYRK2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.